Enterprise Value
834.5M
Cash
63.49M
Avg Qtr Burn
-11.36M
Short % of Float
1.37%
Insider Ownership
4.87%
Institutional Own.
24.45%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Erivedge (vismodegib) Details BCC (Basal Cell Carcinoma) | Approved Quarterly sales | |
CA-4948 (emavusertib)+/- ibrutinib Details Non-Hodgkin lymphoma, Blood cancer, Cancer | Phase 1/2 Data readout | |
CA-4948 (emavusertib) Details Acute myeloid leukemia, Myelodysplastic syndrome, Blood cancer, Cancer | Phase 1/2 Data readout | |
Phase 1/2 Initiation | ||
CI-8993 (anti-VISTA antibody) Details Solid tumor/s, Cancer | Phase 1 Data readout |